Cepheid

Cepheid Inc., headquartered in Sunnyvale, California, is a for-profit manufacturer specializing in advanced molecular diagnostic systems and reagents for detecting infectious diseases and clinical conditions. The company has established itself as a primary federal supplier of diagnostic solutions through its GeneXpert diagnostic platform and associated molecular testing capabilities, serving multiple federal healthcare agencies including the Department of Veterans Affairs, Indian Health Service, Defense Health Agency, Defense Logistics Agency, and the U.S. Coast Guard. Cepheid's core competency lies in providing rapid molecular diagnostic testing for conditions including COVID-19, influenza, respiratory syncytial virus, methicillin-resistant Staphylococcus aureus (MRSA), Clostridioides difficile, tuberculosis, and sexually transmitted infections.

Cepheid has been awarded extensive federal contracts across multiple procurement vehicles and federal agencies, demonstrating substantial capability in supplying molecular diagnostic equipment, reagents, test kits, and maintenance services. The company has received firm fixed-price delivery orders and purchase orders from the Department of Veterans Affairs across numerous Veterans Integrated Service Networks (VISN 1, 2, 4, 5, 6, 7, 8, 9, 10, 12, 15, 16, 19, 21, 22, and 23), with contract values ranging from modest service and supply orders under $100,000 to comprehensive multi-million dollar agreements. Specific contract deliverables include GeneXpert diagnostic systems, molecular diagnostic testing system reagents and assays, PCR test kits for various infectious diseases, maintenance and repair services for diagnostic equipment, cost-per-test services, preventive maintenance contracts, and equipment upgrades. The Indian Health Service has also awarded Cepheid multiple contracts for diagnostic supplies, reagent testing kits, GeneXpert service agreements, and COVID-19 testing kits, reflecting the company's role in supporting tribal healthcare operations across facilities in Montana, New Mexico, Arizona, and Colorado. The Defense Health Agency has contracted with Cepheid for equipment maintenance services, full-service maintenance agreements for GeneXpert diagnostic systems, and RT-PCR analyzer support at military medical centers including Carl R. Darnall Army Medical Center, Naval Medical Center San Diego, and Brooke Army Medical Center. Defense Logistics Agency Medical Supply Chain has issued numerous delivery orders for diagnostic testing supplies, test kits, and reagents. The U.S. Coast Guard awarded Cepheid a contract for essential care maintenance services on GeneXpert Xpress instruments. All of these contracts have utilized firm fixed-price structures with no set-aside designations, indicating Cepheid's competitive positioning in the federal molecular diagnostics procurement market.

Cepheid's federal grant portfolio demonstrates the company's role in advancing diagnostic technology research and global health initiatives. The company has served as a sub-recipient on federal grant awards, most notably receiving a sub-grant from Rutgers The State University of New Jersey with an award date of January 31, 2025, to support research on point-of-care detection of fluoroquinolone, bedaquiline, and linezolid-resistant Mycobacterium tuberculosis for rapid treatment decisions. This grant work aligns with Cepheid's technical expertise in developing molecular diagnostic solutions for drug-resistant tuberculosis detection. Additionally, Cepheid served as a sub-contractor on a May 15, 2023 sub-award from ICF Incorporated, L.L.C., to provide technical support to Uganda by supporting procurement of commodities for micro-dilution broth and whole genome sequencing to adopt newer molecular and phenotypic drug susceptibility testing methods. These grant and sub-award activities demonstrate Cepheid's engagement beyond routine federal procurement, extending to research collaboration and international capacity-building efforts focused on improving diagnostic capabilities for resistant infectious diseases.

Cepheid holds two significant prime Indefinite Delivery Contracts with the Department of Veterans Affairs that establish the framework for extensive ongoing procurement of molecular diagnostic solutions across the federal healthcare system. The company was awarded a single-award Indefinite Delivery Contract by VISN 17 valued at $6,741,574.26 with a ceiling completion date of December 28, 2029, for the provision of diagnostic reagents and test kits specifically designed for the GeneXpert diagnostic platform, including XPRS4PLEX-10 cartridges and XPRS-COV2-10 cartridges for detecting multiple respiratory pathogens. The initial delivery order under this contract, awarded on December 22, 2025, was valued at $1,564,125.00 for the first ordering period. More substantially, Cepheid holds a single-award Indefinite Delivery Contract with VISN 6 valued at $32,800,690.88, extending through September 30, 2030, for the provision of molecular diagnostic testing system reagents and assays to support VISN 6 medical center laboratories. This VISN 6 IDC has generated numerous delivery orders ranging from approximately $41,000 to $970,000, with consistent firm fixed-price structures and no set-aside designations. Both IDV contracts reflect the VA's reliance on Cepheid as a core supplier of molecular diagnostic capabilities, with ordering periods extending through 2030 that enable continuous, demand-driven procurement of testing solutions across multiple VA healthcare facilities. These IDV vehicles serve as the primary contracting mechanism through which Cepheid supplies diagnostic equipment, reagents, test kits, and associated services to support the VA's clinical laboratory operations and infectious disease testing requirements across its distributed network of medical centers and integrated service networks.